

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of New Board Member Dr. Kevin Knopf

June 1, 2013

Cellanyx is pleased to announce the appointment of Dr. Kevin Knopf to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Dr. Kevin Knopf comes to Cellanyx with tremendous scientific and leadership talent. Currently, Dr. Knopf is a clinical Hematologist/Oncologist at the California Pacific Medical Center. He holds an M.D. from the University of California, San Francisco, and a Masters in Public Health from Johns Hopkins University. Dr. Knopf is an expert in health services research that includes cost-effectiveness analysis and cost-utility analysis modeling for cancer therapeutics and devices. Previously, he was a senior visiting scientist at the United Biosource Corporation, specializing in cancer pharmacoeconomics.

Dr. Knopf is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###